Compile Data Set for Download or QSAR
Report error Found 88 Enz. Inhib. hit(s) with all data for entry = 12465
TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704400(2-((1r,4r)-4-((4-(4-(2,6-Dioxopiperidin-3-yl)-3-me...)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704391(6-Cyclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopiper...)
Affinity DataIC50: 0.700nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704405(2-((1r,4r)-4-((4-(6-(2,6-Dioxopiperidin-3-yl)pyrid...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704386(6-Cyclopropoxy-2-(1-(2-(4-((4-(2,4-dioxotetrahydro...)
Affinity DataIC50: 0.800nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704382(US20240374588, Example 50)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704402(US20240374588, Example 72)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704374(2-((1r,4r)-4-((4-(4-(2,4-Dioxotetrahydropyrimidin-...)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704414(US20240374588, Example 91)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704314(US20240374588, Example 7)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704385(US20240374588, Example 53)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704312(US20240374588, Example 5)
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704378(2-((1r,4r)-4-(2-(4-(4-(2,4-Dioxotetrahydropyrimidi...)
Affinity DataIC50: 1.40nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704390(N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-...)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704354(US20240374588, Example 21)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704408(US20240374588, Example 79)
Affinity DataIC50: 1.60nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704418(US20240374588, Example 95)
Affinity DataIC50: 1.60nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704357(2-((1r,4r)-4-((4-(4-(1-(2,6-Dioxopiperidin-3-yl)-3...)
Affinity DataIC50: 1.60nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704321(2-(4-(4-(4-(1-(2,6-Dioxopiperidin-3-yl)-3-methyl-2...)
Affinity DataIC50: 1.70nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704310(US20240374588, Example 3)
Affinity DataIC50: 1.70nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704360(N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-...)
Affinity DataIC50: 1.70nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704307(US20240374588, Example 1)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704372(6-Cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,4-dioxotetra...)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704366(2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)pheny...)
Affinity DataIC50: 1.90nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704377(2-((1r,4r)-4-((4-((4-(2,4-Dioxotetrahydropyrimidin...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704373(2-((1r,4r)-4-((4-(4-(2,4-Dioxotetrahydropyrimidin-...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704389(2-((1r,4r)-4-((4-(1-(2,6-Dioxopiperidin-3-yl)-3-me...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704317(US20240374588, Example 9)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704395(2-((1r,4r)-4-((4-((1-(4-(2,4-Dioxotetrahydropyrimi...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704350(US20240374588, Example 17)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704403(US20240374588, Example 73)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704351(US20240374588, Example 18)
Affinity DataIC50: 2.10nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704375(2-((1r,4r)-4-((4-(4-(2,4-Dioxotetrahydropyrimidin-...)
Affinity DataIC50: 2.20nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704358(N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-...)
Affinity DataIC50: 2.20nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704352(US20240374588, Example 19)
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704387(2-((1r,4r)-4-((4-(4-((2,6-Dioxopiperidin-3-yl)carb...)
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704398(6-Cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,6-dioxopiper...)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704394(2-((1r,4r)-4-((4-((1-(2,6-Dioxopiperidin-3-yl)-3-m...)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704411(US20240374588, Example 86)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704379(N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-...)
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704384(US20240374588, Example 52)
Affinity DataIC50: 2.60nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704365(2-((1r,4r)-4-((4-(4-(2,4-dioxotetrahydropyrimidin-...)
Affinity DataIC50: 2.60nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704410(N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-...)
Affinity DataIC50: 2.70nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704404(2-((1r,4r)-4-(2-(4-(4-(2,6-Dioxopiperidin-3-yl)phe...)
Affinity DataIC50: 2.80nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704353(US20240374588, Example 20)
Affinity DataIC50: 2.80nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704324(US20240374588, Example 13)
Affinity DataIC50: 2.90nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704380(2-((1r,4r)-4-((4-((4-(4-(2,4-Dioxotetrahydropyrimi...)
Affinity DataIC50: 3nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704359(2-((1r,4r)-4-((4-((3-(1-(2,6-Dioxopiperidin-3-yl)-...)
Affinity DataIC50: 3.10nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704409(2-((1r,4r)-4-((4-(2-(2,6-Dioxopiperidin-3-yl)-7-me...)
Affinity DataIC50: 3.10nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704407(N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-...)
Affinity DataIC50: 3.30nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Astrazeneca

US Patent
LigandPNGBDBM704416(2-((1r,4r)-4-((4-(4-(2,4-Dioxotetrahydropyrimidin-...)
Affinity DataIC50: 3.40nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 88 total ) | Next | Last >>
Jump to: